Abstract Inflammatory bowel disease (IBD) is more common in adults than in children. Onset of IBD before 17 years of age is referred as pediatric onset IBD and is further categorized as very early onset IBD (VEO-IBD) for children who are diagnosed before 6 years of age, infantile IBD who had the disease before 2 years of age and neonatal onset IBD for children less than 28 days of life. Children presenting with early onset disease may have a monogenic basis. Knowledge and awareness of the clinical manifestations facilitates early evaluation and diagnosis. Next generation sequencing is helpful in making the genetic diagnosis. Treatment of childhood IBD is difficult; targeted therapies and hematopoietic stem cell transplantation form the mainstay. In this review we aim to summarize the genetic defects associated with IBD phenotype. We describe genetic location and functions of various genetic defect associated with VEO-IBD with their key clinical manifestations. We also provide clinical clues to suspect these conditions and approaches to the diagnosis of these disorders and suitable treatment options.
Introduction
Inflammatory bowel disease (IBD) is a clinical condition which is common among adults. Childhood IBD constitutes about 25% of all patients of IBD. 1 Among these children, there is a subgroup of patients who develop symptoms of IBD at a very early age and may have an underlying genetic basis. 2 The affected children have severe manifestations and complicated clinical course of disease. The Montreal classification of IBD defined childhood IBD with disease onset <17 years as pediatric onset IBD. 3 This was later modified by Paris classification as A1a group for those with onset of IBD <10 years of age and A1b for children with onset of symptoms between 10 and <17 years of age. The A1a group was further subdivided into very early onset IBD (VEO-IBD) for children who are diagnosed before 6 years of age, infantile IBD who developed disease before 2 years of age and neonatal onset IBD for children less than 28 days of life. 4 Even though VEO-IBD constitutes only a small proportion of the total IBD, it is this subset of children who are most likely to have a genetic basis and early recognition and management is necessary to improve the morbidity and mortality. The current review is thus focused on VEO-IBD which includes the infantile and neonatal disease.
Epidemiology
Childhood IBD constitutes about 20e25% of all IBD patients. 5 The incidence of childhood IBD is increasing world over. 6 It may be attributed to increased awareness and better diagnostic tests but may also represent a true increase in the incidence. The annual incidence of childhood IBD is estimated to be 2.2 to 13.3 cases per 100,000 children in Western countries. 6e8 The VEO-IBD has been reported in about 15% of childhood IBD 5 with an incidence and prevalence of 4.37 per 100,000 and 14 per 100,000 children respectively. 6 
Clinical presentation
Childhood IBD can have a myriad of clinical manifestations and children usually present with insidious onset, blood and mucus stained small volume diarrhoea. Occasionally, severe large volume diarrhoea can also occur more often seen in children with immunedysregulation polyendocrinopathy enteropathy X linked (IPEX) syndrome. 9 Intestinal fistula can be seen in children with chronic granulomatous disease (CGD), IL-10 signalling defect and X-linked inhibitor of apoptosis protein (XIAP) due to transmural inflammation of intestine. 10 In addition to gastrointestinal symptoms, infections at other sites are encountered in children who have IBD associated with significant immune deficiencies. 11 There may also be associated somatic defects in skin, hair, teeth and various other ectodermal elements in children with nuclear factor-kB essential modulator (NEMO) mutation and are helpful clinical clues. 12 
Genetics
Most childhood IBD are polygenic in nature. Approximately 163 genetic loci comprising of 300 candidate genes associated with IBD have been detected by genome-wide association studies. However, it was found that each loci contributed only a small portion to the hereditary nature of IBD. 13 However, many children with VEO-IBD have an underlying genetic disorder that causes IBD. Till date, approximately, 50 genetic variants have been associated with IBD and these disorders are collectively called as monogenic IBDs. 14 These genetic conditions lead to aberrations in several mechanisms altering the intestinal immune homeostasis. Thus, monogenic IBDs are best studied based on the following pathophysiological mechanism viz, defective T-cell immune tolerance, epithelial barrier dysfunction, defect in cells regulating inflammation (IL-10 signalling defect), neutrophil dysfunction, combined or isolated defect in T and B-cell, and hyperinflammatory disorders. 15 
Defective T-cell immune tolerance
Various mutation can cause defective T-cell tolerance and the prototype example is immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. Mutations in FOXP3 gene leads to decrease in regulatory T (Treg) cells and hence defective immune tolerance. This results in T and B-cell immune dysregulation resulting in both antibody and cell-mediated GI injury and inflammation (Fig. 1) . 16 The reduced Treg cells leads to autoimmunity which manifests as endocrinopathy, cytopenia, hepatitis and severe eczema. 17 IPEX phenotype can also be caused by various other mutations that decrease Treg cell quantitatively and qualitatively like defect in IL2 signalling due to CD25 mutation, 18 signal transducer and activator of transcription (STAT)-5b, 19 STAT-1 gain-of-function (GOF) mutation, 20 STAT-3 GOF mutation, 21 lipopolysaccharide responsive beige-like anchor protein (LRBA) deficiency, 22 and cytotoxic T-lymphocyte-associated protein (CTLA)-4 haploinsufficiency 23 due to Treg dysfunction (Fig. 1 ).
Epithelial barrier dysfunction
Intestinal immune tolerance is impaired when there is defect in epithelial integrity and function resulting in proinflammatory intestinal milieu and IBD. Tetratricopeptide repeat domain 7A (TTCA7A) deficiency leads to inversion of apicobasal polarity and defective epithelial cell differentiation and poor mucosal barrier function causing IBD. 24 Apart from TTCA7A deficiency, Inhibitor of Kappa Light Polypeptide Gene Enhancer in B cell Kinase Gamma (IKBKG) gene mutation causes IBD like phenotype. 25 IKBKG gene encodes for nuclear factor-kB essential modulator protein (NEMO) and its deficiency leads to defective NF-kB signalling and thereby, become sensitive to proinflammatory cytokine-mediated apoptosis of intestinal cells (Fig. 2) . 26 Moreover, dystrophic epidermolysis bullosa, Kindler syndrome, familial diarrhoea caused by dominant activating mutations in guanylate cyclase C, a disintegrin and metalloproteinase domain 17 (ADAM17) deficiency from biallelic loss of function in ADAM17 gene, 27 dyskeratosis congenita (DKC), 28 and regulator of telomere elongation helicase 1 (RTEL1) are known to present with varying immune deficiency and enterocolitis as they have defective epithelial barrier 29 (Fig. 2) .
Defect in cells regulating inflammation (IL10 signalling defect)
IL10 is an immunomodulatory cytokine produced by Treg cells, macrophages and B cells. Loss of function mutation in 
Neutrophil dysfunction
Chronic granulomatous disease (CGD) is characterised by phagocytic dysfunction due to genetic defect in components of NADPH oxidase complex viz, gp91-phox (CYBB), p22-phox (CYBA), p47-phox (NCF1), p67-phox (NCF2), and p40-phox (NCF4). CGD is known to cause intestinal inflammation and IBD like phenotype. The defect in NADPH oxidase leads to defect in NF-kB signalling, activation of inflammasome and neutrophil apoptosis, ultimately, leading to hyperinflammation. 34 Recently, missense variant of NCF2 affecting RAC2 binding sites are also noted to manifest as VEO-IBD. 35 Moreover, several heterozygous hypomorphic variants in components of NOX2 NADPH oxidase complex were detected in patients with VEO-IBD. 36 In addition to CGD, a number of other neutrophil defects are associated with intestinal inflammation. Defects in glucose-6-phosphate-translocase (SLC37A4) and glucose-6-phosphatase-catalytic subunit 3 (G6PC3) predispose individuals to IBD along with neutropenia. Defect in any of these two genes create hypoglycolytic monocytes and neutrophils lendering them with defective microbial killing capacity. 37, 38 Some patients with leukocyte adhesion deficiency type 1 (mutation in ITGB2 encoding CD18 are also reported to have IBD like manifestations as they have persistent inflammation due to defective neutrophil migration to the site of inflammation. 39 Lastly, glycogen storage disease type Ib, characterized by neutropenia and neutrophil granulocyte dysfunction also has IBD like manifestations 40 (Fig. 3) .
Combined or isolated T and B cell defect
IBD phenotype is one of the common manifestations of T cell or B cell defect. Hypomorphic mutation of genes such as DCLRE1C, ZAP70, RAG2, IL2RG, LIG4, ADA, and CD3G can lead to leaky SCID with some residual dysregulated, autoreactive and oligoclonal T cells. These variant of SCID is known to present with VEO-IBD. 41, 42 Another primary immunodeficiency disease that is associated with VEO-IBD is Wiskott-Aldrich syndrome (WAS). It is an X-linked, recessive disease caused by subnormal expression of WASP due to Figure 3 Neutrophil dysfunction: involvement of molecules, indicated through red circles which can cause inflammatory bowel disease. a. Subunits of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase are involved in secreting reactive oxygen species (ROS). b. Glucose-6-phosphate dehydrogenase (G6PT) transports glucose from cytoplasm to endoplasmic reticulum. G6PTase-a phosphorylates glucose to continue glycolysis. c. Integrin on binding to its substrate, initiates AKT pathway and helps in cell survival. Moreover, B-cell defects like X-linked agammaglobulinemia (Bruton tyrosine kinase mutation), common variable immunodeficiency (CVID) and Hyper IgM syndrome can also present with IBD. These defects has abnormal B cells function and thus defective immunoglobulin production resulting in prolonged inflammation. 45, 46 Other disorders IBD and IBD like phenotype have been reported in various others disorders. Loss of function mutations in Transforming Growth Factor B 1 (TGFb1) have been identified to cause infantile IBD. 47 TGF b regulate various cellular functions like inflammatory responses, cell proliferation, apoptosis and extracellular matrix remodelling. 48 VEO-IBD has also been reported with loss of function mutation of intestinal alkaline phosphatase. 49 It maintain gut homeostasis by increasing tolerance towards commensal bacteria by dephosphorylating lipopolysaccharide (LPS), outer membrane component of gram negative bacteria. LPS, thereby, unable to bind to toll like receptor 4 (TLR4), which prevents the downstream proinflammatory signalling. 50, 51 Another entity called Receptor Interacting Serine/Threonine Kinase1 (RIPK1) also has a role in VEO-IBD. RIPK1 is a cytosolic protein kinase that mediates signal transduction for apoptosis, necroptosis and inflammation which gets activated through TLRs pathway. RIPK1 either gets ubiquitylated and activates NF-kB and proinflammatory signalling or phosphorylated and activates necroptosis of the cell.
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RIPK1 deficiency due to homozygous mutations in RIPK1 is characterised by recurrent infections, lymphopenia, early onset IBD and polyarthritis. 53 VEO-IBD is also described in several other immunodeficiency and autoinflammatory disorder like defects in the Itchy E3 Ubiquitin Protein Ligase activity encoded by ITCH gene and defects in E3 ubiquitin ligase HOIL-1 encoded by HOIL1. 54, 55 The genetic basis of monogenic IBD are summarised with gene location and function in Table 1 .
Clinical clues to very early onset/monogenic IBD
The onset of colitis presenting at very early age, particularly below 2 years should raise a suspicion of VEO-IBD. The history of consanguinity or family history of VEO-IBD gives an additional clue to the underlying genetic etiology. The presence of other associated symptoms of ectodermal changes like trichorrhexis nodosa, superficial skin abscesses, bullous epidermolysis and eczematous skin lesions point towards monogenic IBD. Children may have recurrent or atypical infections with severe and early onset perianal fistulas due to underlying immune deficiencies and may occasionally be the presenting manifestation. There may be associated autoimmune haemolytic anemia, thyroiditis, arthritis, sclerosing cholangitis, serosal inflammation, 
Management protocols for putative immunodeficiency in VEO-IBD
Children with VEO-IBD usually respond poorly to conventional immunosuppressive therapy of IBD. Many therapeutic options including biologics have given promising results in this disorder. The understanding of underlying pathogenic mechanisms and genetic defects help to employ a targeted therapy. Colitis in CGD has been found to be responsive to anakinra, an IL-1b antagonist. 56 Anakinra inhibits inflammasome and thereby, augments autophagy. Still, treatment response may not sustain for long and satisfactory response is obtained in only a subgroup of CGD associated colitis. 57 Abatacept shows good results in children with colitis in LRBA deficiency and CTLA4 haploinsufficiency as it blocks T-cell costimulatory pathway. 58 Similarly, colitis associated with STAT3 GOF mutation is responsive to tocilizumab, an IL-6 receptor blocking antibody. 59 Sirolimus improves Treg cell function and has been used in IPEX and its phenocopies. 60 Children who respond poorly to medical therapy may benefit from colectomy and hematopoietic stem cell transplantation (HSCT). In IPEX and IL-10 signalling defects, HSCT has been shown to improve colitis and gastrointestinal fistulas. 61, 62 However, IBD associated with primary ectodermal defects (NEMO, TTC7a deficiency) fails to improve and may even worsen following HSCT. 24, 63 Lastly, gene therapy is a future prospect in the management of monogenic IBD. 64, 65 Current challenges in VEO-IBD Even though these disorders are rare, they are increasingly being recognised due to better awareness among physicians. Yet, they remain a diagnostic challenge. Identifying the underlying genetic disorder is imperative for introducing optimal therapeutic options. Biologic therapy is effective but, not a curative modality of treatment for VEO-IBD. Long term data of children on biologic therapy is scarce in literature. Experience of curative HSCT in certain conditions is promising however, it should always be individualised.
To conclude, monogenic IBD has high morbidity and mortality. Among children presenting with colitis at very early age, a high index of suspicion for monogenic IBD must be entertained. Early institution of genetic diagnosis should be made to assess prognosis and plan for appropriate therapeutic modalities.
